Replies to post #204768 on Biotech Values

[DewDiligence]

ENTA—Good news that will positively impact approval date.

I'm not sure the BTD in a specific patient subgroup will expedite FDA approval of ABT-493/ABT-530 in the general HCV population.

I have not heard if Gilead has received [BTD] for its triple therapy.

I don't think it has (yet).